New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2013
13:09 EDTTIVO, PLCE, GME, HUM, ACN, BIIBOptions with decreasing implied volatility: TIVO PLCE GME HUM ACN BIIB
News For TIVO;PLCE;GME;HUM;ACN;BIIB From The Last 14 Days
Check below for free stories on TIVO;PLCE;GME;HUM;ACN;BIIB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 19, 2014
09:28 EDTGMEGameStop says CEO underwent unexpected surgery for tumor
GameStop disclosed in a regulatory filing that late last week Paul Raines, its CEO, underwent unexpected surgery during which a "very small, cancerous tumor was identified and successfully removed from an easily accessible part of the brain." The company added, "Because it was found very early, his doctors have advised him that his prognosis for a full and complete recovery is very good. The next step is for Paul to undergo preventive chemotherapy. Recovery from this process is expected to take about six weeks. This regimen will restrict his travel during that period, but will not interfere with his continued leadership of the Company." Daniel DeMatteo, Executive Chairman, said, "Speaking for the Board, we have every confidence in Paulís continued leadership and wish him a speedy recovery. While he recovers, our highly-tenured executive team will ensure that our business continues without interruption."
06:11 EDTGMEGameStop FY14 guidance likely in-line, says Piper Jaffray
Subscribe for More Information
August 15, 2014
18:35 EDTBIIBBiogen PLEGRIDY approved in U.S. for treatment of multiple sclerosis
Biogen Idec announced that the FDA has approved PLEGRIDY, a new treatment for people with relapsing forms of multiple sclerosis, or RMS. PLEGRIDY is dosed once every two weeks and can be administered subcutaneously with the PLEGRIDY PEN, a new, ready-to-use autoinjector, or a prefilled syringe. The FDA approval of PLEGRIDY is based on results from one of the largest pivotal studies of beta interferon conducted, ADVANCE, which involved more than 1,500 MS patients.
07:43 EDTPLCEChildren's Place expectations washed out, says Oppenheimer
Subscribe for More Information
07:01 EDTBIIBIsis Pharmaceuticals earns $2M from advancement of ISIS-SMN from Biogen
Isis Pharmaceuticals (ISIS) announced that it has earned a $2M milestone payment from Biogen (BIIB) related to the advancement of the ongoing open-label extension study of ISIS-SMNRx in children with spinal muscular atrophy.
06:01 EDTGMEJuly NPD video game software sales fell 15%, says Piper Jaffray
Subscribe for More Information
August 14, 2014
08:06 EDTHUMHumana management to meet with Oppenheimer
Subscribe for More Information
08:05 EDTHUMHumana management to meet with UBS
Meetings to be held in Denver/Minneapolis on August 14 hosted by UBS.
August 12, 2014
06:35 EDTHUMManged Care recent pullback a buying opportunity, says Leerink
Subscribe for More Information
August 11, 2014
10:50 EDTBIIBBiogen weakness attributed to Forward Pharma IPO filing
Shares of Biogen Idec (BIIB) came off their earlier highs and moved into negative ground in early trading, with some attributing the move lower to another pharmaceutical company, Forward Pharma (FWP), filing its registration statement with the SEC relating to a proposed initial public offering and reporting that Joel Sendek has been appointed CFO. WHAT'S NOTABLE: Forward Pharma focuses on a proprietary formulation of dimethyl fumarate, or DMF, for the treatment of multiple sclerosis. DMF is the Active Pharmaceutical Ingredient, or API, found in Tecfidera, which Biogen Idec began selling for the treatment of RRMS following approval by the FDA in March 2013 and approval by the European Commission in February 2014, Forward Pharma indicated in its IPO filing. In addition to its filing, Forward Pharma announced this morning that it has hired Joel Sendek from Stifel Financial, where he served as Managing Director, Biotechnology and led the firm's healthcare equity research group. PRICE ACTION: Shares of Biogen are down fractionally in mid-morning trading after being up over 1% soon after today's opening bell.
August 8, 2014
06:30 EDTACNCitigroup, Accenture employ tech workers in Argentina, Bloomberg says
Subscribe for More Information
August 7, 2014
13:23 EDTHUMLeerink healthcare services analyst holds an analyst/industry conference call
Subscribe for More Information
10:51 EDTBIIBOptions with increasing implied volatility
Subscribe for More Information
August 6, 2014
07:19 EDTBIIBAkebia names Brad Maroni as Chief Medical Officer
Akebia Therapeutics (AKBA) announced the expansion of its senior management team with three key additions: Brad Maroni, M.D., as Senior Vice President and Chief Medical Officer, Mark De Rosch, Ph.D., as Vice President of Regulatory Affairs and Tamara Dillon as Vice President of Human Resources. Maroni most recently served as Vice President, Medical Research at Biogen Idec (BIIB).
06:38 EDTACNAccenture says complying with SAIC in Microsoft probe, Reuters says
Subscribe for More Information
06:35 EDTACNSAIC enacts fresh raids on Accenture, Microsoft, Reuters says
China's State Administration for Industry and Commerce said on its website that it conducted fresh raids on Microsoft (MSFT) and Accenture (ACN) after the firm noted last week that Microsoft is being probed for anti-trust crimes, according to Reuters, citing an e-mail statement from a Beijing-based Microsoft spokeswoman. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use